Meningococcal Vaccines Global Market Size ($5.69 Billion Revenue By 2028) Growing Rapidly with Recent Trends and Outlook

"The new report published by The Business Research Company, titled ""Meningococcal Vaccines Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the meningococcal vaccines market size has grown rapidly in recent years. It will grow from $3.57 billion in 2023 to $3.94 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $5.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=8013&type=smp

Impact Of Rising Healthcare Spending On Meningococcal Vaccines
An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination is becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in May 2022, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, healthcare spending in the United States had risen by 9.7% to $4.1 trillion, or $12,530 per person. This pace of growth is significantly higher than 2019's (4.3%). Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine market.

Pfizer's Comprehensive Meningococcal Vaccine With FDA Approval
Major companies operating in the meningococcal vaccines market are developing new vaccines for the prevention of serogroups to increase their profitability in the market. Meningococcal vaccines are preventive measures designed to protect individuals against infections caused by specific serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company received approval from FDA for the vaccine PENBRAYA. PENBRAYA, with extensive serogroup coverage, is the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. FDA approval is grounded in robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with favorable safety. Pfizer's September 2022 announcement revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.

The meningococcal vaccines market covered in this report is segmented -
1) By Vaccine Type: Meningococcal Conjugate Vaccine, Polysaccharide, Subcapsular Vaccine
2) By Serotype: Men Acwy, Men B/Bc, Men C
3) By Age Group: Infants, Children, Adolescents and Young Adults, Adults
4) By Distribution Channel:: Pharmacies, Community Clinics, Public Health Agencies, Other Channels
5) By End user: Hospitals, Research, Academic Institutes

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=8013&type=discount

Major companies operating in the meningococcal vaccines market report are Pfizer Inc., Johnson and Johnson Services Inc., Sinopharm Group Co Ltd., Merck & CoInc., Novartis AG, Sanofi S.A, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Seqirus Pty Ltd., Sinovac Biotech Ltd., Emergent BioSolutions Inc., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., Beximco Pharmaceuticals Ltd., Bavarian Nordic A/S, JN-International Medical Corporation, Valneva SE, Serum Institute of India Pvt Ltd., Incepta Pharmaceuticals Ltd., Biological E. Limited, LG Chem Life Sciences Company, Chongqing Zhifei Biological Products Co, Protein Sciences Corporation, Bharat Biotech Ltd., Bio-Med Limited, Bio-Manguinhos, Nuron Biotech Ltd.

Contents of the report:
1. Executive Summary
2. Meningococcal Vaccines Market Report Structure
3. Meningococcal Vaccines Market Trends And Strategies
4. Meningococcal Vaccines Market - Macro Economic Scenario
5. Meningococcal Vaccines Market Size And Growth
…..
27. Meningococcal Vaccines Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.